ImmunoQure AG - Science

SCIENCE

ImmunoQure is focusing on the discovery of patient-selected antibodies for the treatment of inflammatory and autoimmune diseases.

At ImmunoQure AG we are breaking new ground in the research and development of naturally occurring human antibodies as therapeutics for the treatment of common human diseases.

The human immune system is designed to mount effective antibody responses against foreign proteins for combatting infectious diseases caused by invading viral, bacterial and fungal agents. However, in rare cases, the human immune system makes antibodies against endogenous human proteins. Such antibodies are called autoantibodies.

ImmunoQure’s technology platform allows us to retrieve meaningful, natural human autoantibodies against relevant human drug targets that are the root cause of common diseases. For the discovery of such autoantibodies, we are collaborating closely with rare autoimmune disease patients who harbor unique sets of autoantibodies that are absent in the normal human population.

STRATEGY / SCIENTIFIC APPROACH

ImmunoQure’s goal is to become a strong alliance partner for pharmaceutical and biopharmaceutical companies prior to the initiation of IND activities.

Using our novel patient-driven human antibody platform, we are focusing on developing multiple pre-IND programs in parallel and entering into partnerships for the further clinical development of these products.
.
.
.

Our approach is to identify and develop the most relevant autoantibodies from these highly selected patient populations based on defined aspects of their clinical history.

Human-derived antibodies are ideal therapeutic agents because of their excellent safety profile and inherent efficacy, offering a superior therapeutic window over other traditional therapeutic modalities including small molecules and engineered antibodies. Having been crafted by nature, ImmunoQure’s antibodies do not need further optimization and represent fast-track, safe and efficacious IND candidates. Our initial focus is on the development of naturally engineered human antibodies as biological therapies for the treatment of autoimmune and inflammatory diseases.
.
.

.
.

ImmunoQure is establishing an expanding pipeline of high-impact first-in-class and best-in-class natural human antibody therapeutics for combatting multiple human diseases. While our initial focus is in the field autoimmune and inflammatory diseases, we are actively seeking collaborative opportunities for applying our human-derived antibody discovery platform to additional human disease areas with high medical need.

Human-derived antibodies recognizing a cytokine involved in multiple autoimmune and inflammatory diseases have been identified, cloned, and characterized. In vitro mechanism-of-action and in vivo efficacy studies have been completed.

Human-derived antibodies recognizing a cytokine involved in multiple autoimmune and inflammatory diseases have been identified, cloned, and characterized. In vitro mechanism-of-action and in vivo efficacy studies have been completed.

Human-derived antibodies recognizing a key regulator of discrete cytokine signaling networks involved in multiple autoimmune and inflammatory diseases have been identified, cloned and characterized. In vitro mechanism-of-action studies have been completed.

Human-derived antibodies recognizing a family of cytokines involved in multiple autoimmune and inflammatory diseases have been identified, cloned, and characterized.